- Details
- In this UroToday Journal Club Christopher Wallis and Zachary Klaassen highlight the Journal of clinical oncology publication of the phase II SALV-ENZA Trial which sought to investigate whether enzalutamide, without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen progression when combined with salvage radiation therapy in men with recurrent prostate cancer...
|
- Details
- In this UroToday Journal Club Christopher Wallis and Zachary Klaassen highlight the Urologic Oncology publication entitled Out-of-pocket costs for commercially insured patients with localized prostate cancer. Financial burdens may contribute to long-term effects on patient's health-related quality of life. However, costs are rarely included in shared decision-making conversations, and most studies...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication entitled "Association Between Treatment for Localized Prostate Cancer and Mental Health." This study compares patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over 5 years using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Biographi...
|
- Details
- In this UroToday Journal Club, Chris Wallis and Zach Klaassen highlight a European Urology Oncology publication entitled Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Biopsy in Men on Active Surveillance for Prostate Cancer -- Data from the Multi-International Multicenter Prospective PRIAS Study . In general, the use of MRI prior to initial biopsy is now relativ...
|
- Details
- In this UroToday Journal Club, Chris Wallis and Zach Klaassen highlight a European Urology publication entitled High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium . Radiotherapy is a standard-of-care treatment approach for patients with localized prosta...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the PROpel study and the New England Journal of Medicine Evidence publication entitled Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer . PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castr...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Journal of clinical oncology publication entitled Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials . The authors use two independent phase II trials, each of which enrolled men with oligometa...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Nature Medicine publication entitled Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nivo and ipi first demonstrated to have a benefit in this setting in the CheckMate 214 trial. However, the vast majority of patients still don't...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Lancet publication Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Approximately 80% of patients, present initially with local regional disease. However, despite the i...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review The Lancet Oncology publication High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05) looking at its 10-year results. Radiotherapy is a standard treatment option in patients with localized prostate cancer. With conventional dosing of radiotherapy, the addition of androgen...
|
